TOPICS

2024/03/11
新しいハイスループット腎毒性スクリーニングシステムの創生

2024/03/01
High Throughput Zebrafish Nephrotoxity Screening Systems

2024/01/04
240101謹賀新年

2023/12/28
ゼブラフィッシュ創薬ウェビナー

2023/10/31
ゼブラフィッシュ創薬とマウス創薬の比較

》oncocardiology of sorafenib

                     
2023/04/28

Oncocardiology is a subspecialty of cardiology that focuses on the prevention, diagnosis and treatment of cardiovascular complications caused by cancer therapies. Sorafenib is a tyrosine kinase inhibitor that is used to treat advanced hepatocellular carcinoma and renal cell carcinoma. However, sorafenib can also induce cardiotoxicity, such as hypertension, left ventricular dysfunction, heart failure and ischemia. The characterization of oncocardiology of sorafenib involves the identification of risk factors, biomarkers and imaging modalities that can help to monitor and manage the cardiac effects of this drug. Additionally, the characterization of oncocardiology of sorafenib requires the development of strategies to prevent or mitigate cardiotoxicity, such as dose adjustment, drug interruption or discontinuation, and the use of cardioprotective agents.

関連リンク

三重大学大学院医学系研究科システムズ薬理学

三重大学メディカルゼブラフィッシュ研究センター